Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 15/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.35 |
| ▸ | AURKA | O14965 | 3/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3069029 | 1.00 | EGFR (0.38) | EGFRCHEK1AURKANPC1RAB9A | |
| SCHEMBL3079930 | 0.91 | MAP3K7 (0.39) | EGFRCHEK1AURKA | |
| SCHEMBL3079927 | 0.91 | MAP3K7 (0.39) | EGFRCHEK1AURKA | |
| SCHEMBL13093749 | 0.91 | EGFR (0.35) | EGFRAURKANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3062507 | 0.87 | EGFR (0.35) | EGFRCHEK1AURKA | |
| SCHEMBL3062503 | 0.87 | EGFR (0.35) | EGFRCHEK1AURKA | |
| SCHEMBL3067804 | 0.86 | AURKA (0.37) | EGFRCHEK1AURKA | |
| SCHEMBL3067808 | 0.86 | AURKA (0.37) | EGFRCHEK1AURKA | |
| SCHEMBL3072332 | 0.86 | AURKA (0.39) | EGFRCHEK1AURKA | |
| SCHEMBL3079948 | 0.85 | AURKA (0.36) | EGFRCHEK1AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100267749-A1 | TRISUBSTITUTED FUROPYRIMIDINES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-10-21 | — | — | US | disclosed |
| US-20100267749-A1 | TRISUBSTITUTED FUROPYRIMIDINES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-10-21 | — | — | US | disclosed |
| US-20100267749-A1 | TRISUBSTITUTED FUROPYRIMIDINES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267749-A1 | TRISUBSTITUTED FUROPYRIMIDINES AND USE THEREOF | DPYD, TPMT, TYMS | EGFR 3016/4885CHEK1 915/4885AURKA 2963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.